Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 11/20 | 0.69 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.67 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8179931 | 0.86 | PDE10A (0.64) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL9015180 | 0.85 | MAOB (0.67) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL7975209 | 0.85 | CYSLTR1 (0.61) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL8171385 | 0.85 | CYSLTR1 (0.51) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL8180239 | 0.85 | CYSLTR1 (0.51) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL9215770 | 0.85 | CYSLTR1 (0.64) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL8187205 | 0.85 | CYSLTR1 (0.57) | CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL8179251 | 0.85 | CYSLTR1 (0.52) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL6088376 | 0.84 | CYSLTR1 (0.72) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL8186157 | 0.83 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2GPBAR1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1652839-A2 | Drug efflux pump inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-05-03 | — | — | EP | disclosed |
| EP-1227084-B1 | DRUG DISCHARGE PUMP INHIBITORS | TRINE PHARMACEUTICALS INC (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20030220373-A1 | Therapeutic uses of PPAR mediators | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2003-11-27 | — | — | US | disclosed |
| EP-1267874-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | Aventis Pharma Deutschland GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1030665-A4 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARM PROD INC (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1227084-A1 | DRUG DISCHARGE PUMP INHIBITORS | Microcide Pharmaceuticals, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| WO-2001066098-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-09-13 | — | — | WO | disclosed |
| EP-1030665-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | Aventis Pharmaceuticals Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| EP-0643045-B1 | Quinoline derivatives as leukotriene antagonists | NOVARTIS AG (CH) | 2000-03-08 | — | — | EP | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4904786-A | Quinoline compounds as antiallergic and antiinflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-02-27 | — | — | US | disclosed |
| WO-1989005294-A1 | SUBSTITUTED QUINOLINES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LØVENS KEMIS (DK) | 1989-06-15 | — | — | WO | disclosed |
| EP-0315399-A2 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4826987-A | Pyridyl and quinoline derivatives | LEO PHARMACEUTICAL PRODUCTS LTD. (DK) | 1989-05-02 | — | — | US | disclosed |
| EP-0284174-A1 | Therapeutic preparations | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-28 | — | — | EP | disclosed |
| US-4772703-A | LIPOXYGENASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0261539-A2 | Substituted phenyl-sulphon amides | BAYER AG (DE) | 1988-03-30 | — | — | EP | disclosed |
| EP-0232954-A2 | Heterocyclic sulphonamides | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4675405-A | Quinoline compounds as antiallergic and antithrombotic agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220373-A1 | Therapeutic uses of PPAR mediators | PPARG, PPARA, PPARD | CYSLTR1 297/4885CYSLTR2 422/4885GPBAR1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.